• hormone therapy

    New Research from the CWMH: History of Depression and Anxiety Predict Lower Quality of Life in Midlife Women

    The National Comorbidity Survey estimates that by the time women reach midlife, approximately 23% have experienced at least one episode of major depression and 30% have been diagnosed with an anxiety disorder.  Depression and anxiety disorders are each associated with impaired functioning and lower quality of life (QOL).  There is also some data to suggest that, even after a depressive episode resolves, those with a history of a affective illness have a lower quality of life than those without histories of depression, with impairment in social and interpersonal functioning.

    In Brief: Menopausal Symptoms Usually Go Untreated

    In this study, half of women aged 45 to 60 years reported experiencing menopausal symptoms. 69% of these women reported that their symptoms have negatively  affected their lives. Among the women who endorsed menopausal symptoms, 72% had not received any treatment for their symptoms and 77% reported that they had not discussed treatment options with their healthcare providers.

    New Research from the CWMH: Progestins Do Not Negatively Affect Mood in Peri- and Postmenopausal Women

    More than half of all women initiating treatment with hormone therapy will stop within the first year of treatment, most often because of side effects.  Mood disturbance is a relatively common side effect that occurs with hormone therapy, and previous studies have suggested that progestins in the combined hormone preparations are responsible for these negative mood effects.

    NAMS Supports the Use of Hormone Therapy in Perimenopausal and Recently Postmenopausal Women

    The North American Menopause Society (NAMS) has updated its 2010 recommendations regarding the use of postmenopausal hormone therapy (HT) based on evidence accumulated subsequent to the previous report.  In the decade since the first publication of the results from the Women's Health Initiative, we have accumulated evidence to indicate that multiple factors influence the effects of hormone therapy, including the type of estrogen used, the way the hormones are given, and the age and recency of menopause of the woman taking the medication. These factors also determine the risks associated with hormone therapy. 

    The Truth About Bioidentical Hormones

    In increasing numbers, women who are candidates for hormonal replacement therapy are requesting “bioidentical” rather than synthetic hormones.  Although there is a tendency to think of bioidentical hormones as “all-natural”, they, like synthetic hormones, are manufactured in the laboratory.  In contrast to synthetic hormones, they are chemically identical to the hormones produced by the human body; synthetic hormones are structurally different yet are designed to have similar biological effects as naturally produced hormones.

    By |2015-04-14T22:59:40-04:00November 23rd, 2009|Menopausal Symptoms|5 Comments

    Testosterone Patch Improves Sexual Functioning in Postmenopausal Women

    Sexual dysfunction is common among postmenopausal women and include a spectrum of problems, including low (or hypoactive) sexual desire, decreased satisfaction, and discomfort.   Reports indicate that the prevalence of hypoactive sexual desire ranges from 9% in naturally postmenopausal women up to 26% in younger surgically postmenopausal women.   A recent study published in the New England Journal of Medicine evaluates the effectiveness of the testosterone patch for postmenopausal women with low sexual desire.

    By |2015-08-12T12:08:50-04:00December 1st, 2008|Menopausal Symptoms|1 Comment

    Estrogen for the Treatment of Women with Schizophrenia

    There is cumulative evidence suggesting that estrogen might play a role in the development of schizophrenia and therefore may be useful in the treatment of this illness. On average, the first signs of schizophrenia appear 3 to 4 years later in women than in men, with a second peak in women around menopause.  Interestingly, men suffering from schizophrenia exacerbation demonstrate low serum estrogen and androgen levels.  Estrogen has been demonstrated to have beneficial effects in treating hormonally mediated affective disorders such as postnatal depression or perimenopausal depression.  A recent study published in the Archives of General Psychiatry suggests that estrogen may also be beneficial for the treatment of patients with schizophrenia.

    By |2015-08-11T14:46:54-04:00September 22nd, 2008|Menopausal Symptoms|0 Comments

    Paroxetine CR May Be Helpful for Menopausal Women Discontinuing Hormone Therapy

    Estrogen was first approved by the FDA for the treatment of menopausal symptoms in 1942, and for many decades estrogen replacement therapy had been widely prescribed for peri- and post-menopausal women. In 2002, however, data from the Women’s Health Initiative (WHI) suggested that hormonal therapy may be associated with an increased risk of breast cancer and cardiovascular disease. These findings have led to a dramatic decrease in the use of hormone replacement therapy (HRT), with many women abruptly discontinuing its use.

    By |2015-07-28T10:53:58-04:00November 12th, 2007|Menopausal Symptoms|1 Comment

    Perimenopause: A Time of Risk for Depression

    More than 50 percent of women experience some perimenopausal symptoms, including hot flushes, night sweats, and sleep disturbance, before reaching the menopause. A recent article from Aetna Intelihealth notes that many women may also experience depression. In a study form Dr. Claudio Soares, women with clinically confirmed perimenopause were interviewed:

    Go to Top